HK1252958A1 - 單臂i型和ii型受體融合蛋白和其用途 - Google Patents

單臂i型和ii型受體融合蛋白和其用途

Info

Publication number
HK1252958A1
HK1252958A1 HK18112315.3A HK18112315A HK1252958A1 HK 1252958 A1 HK1252958 A1 HK 1252958A1 HK 18112315 A HK18112315 A HK 18112315A HK 1252958 A1 HK1252958 A1 HK 1252958A1
Authority
HK
Hong Kong
Prior art keywords
type
fusion proteins
receptor fusion
arm
arm type
Prior art date
Application number
HK18112315.3A
Other languages
English (en)
Inventor
Ravindra Kumar
Asya Grinberg
Dianne S Sako
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of HK1252958A1 publication Critical patent/HK1252958A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18112315.3A 2015-04-06 2018-09-26 單臂i型和ii型受體融合蛋白和其用途 HK1252958A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562143579P 2015-04-06 2015-04-06
US201562259422P 2015-11-24 2015-11-24

Publications (1)

Publication Number Publication Date
HK1252958A1 true HK1252958A1 (zh) 2019-06-06

Family

ID=57015654

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112315.3A HK1252958A1 (zh) 2015-04-06 2018-09-26 單臂i型和ii型受體融合蛋白和其用途

Country Status (21)

Country Link
US (3) US10358476B2 (zh)
EP (2) EP3280727B1 (zh)
JP (2) JP6810702B2 (zh)
KR (1) KR20170141215A (zh)
CN (3) CN113683709A (zh)
AU (2) AU2016246602B2 (zh)
CA (1) CA2981793A1 (zh)
CY (1) CY1124247T1 (zh)
DK (1) DK3280727T3 (zh)
ES (1) ES2864850T3 (zh)
HK (1) HK1252958A1 (zh)
HR (1) HRP20210411T1 (zh)
HU (1) HUE054180T2 (zh)
LT (1) LT3280727T (zh)
MA (1) MA53883A (zh)
MD (1) MD3280727T2 (zh)
PL (1) PL3280727T3 (zh)
PT (1) PT3280727T (zh)
RS (1) RS61728B1 (zh)
SI (1) SI3280727T1 (zh)
WO (1) WO2016164501A1 (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
PT3280727T (pt) 2015-04-06 2021-04-23 Acceleron Pharma Inc Proteínas de fusão do recetor de braço único do tipo i e tipo ii e respetivas utilizações
AU2016246708B2 (en) 2015-04-06 2020-12-24 Acceleron Pharma Inc. ALK7:actRIIB heteromultimers and uses thereof
KR20180035884A (ko) 2015-08-04 2018-04-06 악셀레론 파마 인코포레이티드 골수증식성 장애를 치료하기 위한 방법
US20180086806A9 (en) * 2016-04-06 2018-03-29 Acceleron Pharma, Inc. Bmprii polypeptides and uses thereof
EP3439741A4 (en) 2016-04-06 2020-05-06 Acceleron Pharma Inc. ALK7 ANTAGONISTS AND USES THEREOF
AU2017338915A1 (en) 2016-10-05 2019-04-18 Acceleron Pharma Inc. TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
BR112019006993A2 (pt) 2016-10-05 2019-09-03 Acceleron Pharma Inc heteromultímeros de alk4:actriib e usos dos mesmos
CA3039525A1 (en) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Variant actriib proteins and uses thereof
JP7139326B2 (ja) 2016-11-10 2022-09-20 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物
AU2018214979A1 (en) * 2017-02-01 2019-08-15 Acceleron Pharma Inc. TGFβ and actrii antagonists for use in increasing immune activity
WO2018204594A1 (en) 2017-05-04 2018-11-08 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof
US11484573B2 (en) 2017-11-09 2022-11-01 Keros Therapeutics, Inc. Activin receptor type IIa variants and methods of use thereof
WO2019136043A1 (en) * 2018-01-03 2019-07-11 Acceleron Pharma Inc. Single-arm co-receptor fusion proteins and uses thereof
JP7510875B2 (ja) 2018-01-12 2024-07-04 ケロス セラピューティクス インコーポレイテッド アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物
EP3749682A4 (en) * 2018-02-09 2021-11-17 Acceleron Pharma Inc. METHOD OF TREATMENT OF HETEROTOPIC OSSIFICATION
CA3093468A1 (en) 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
WO2019213442A1 (en) * 2018-05-03 2019-11-07 Acceleron Pharma Inc. MULTISPECIFIC BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF
WO2020042647A1 (zh) * 2018-08-28 2020-03-05 北京永泰瑞科生物科技有限公司 改进的治疗性t细胞
CA3147621A1 (en) * 2019-07-18 2021-01-21 Memorial Sloan Kettering Cancer Center Methods and compositions for targeting tgf-.beta. signaling in cd4+ helper t cells for cancer immunotherapy
US20230190875A1 (en) * 2019-12-10 2023-06-22 Acceleron Pharma Inc. Single-arm actriia and actriib heteromultimers and methods for treating pulmonary hypertension
WO2021183819A1 (en) * 2020-03-13 2021-09-16 Acceleron Pharma Inc. Single-arm actriia and actriib heteromultimers and methods for treating renal diseases or conditions
CN112190694B (zh) * 2020-09-17 2023-11-10 南通大学 细胞因子活化素c在治疗神经病理性疼痛方面的应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0105014B1 (en) 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Repair of tissue in animals
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US7592428B1 (en) 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
NZ306767A (en) 1995-04-11 2000-03-27 Univ Johns Hopkins Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
JP2003517580A (ja) 1999-01-21 2003-05-27 メタモーフイクス・インコーポレーテツド 増殖分化因子インヒビター及びそれらの用途
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US20070184052A1 (en) * 2003-05-09 2007-08-09 Lin Herbert Y Soluble tgf-b type III receptor fusion proteins
JP5033420B2 (ja) 2003-09-15 2012-09-26 リサーチ ディベロップメント ファウンデーション アクチビン及びＴＧＦ−ｂのシグナリングのＣｒｉｐｔｏによる拮抗方法
JP4870569B2 (ja) * 2003-11-13 2012-02-08 ハンミ ホールディングス カンパニー リミテッド 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法
DK2332977T3 (en) 2004-07-23 2016-02-29 Acceleron Pharma Inc ActRII receptor polypeptides
CA2631013C (en) 2005-11-23 2019-06-11 Acceleron Pharma Inc. Activin-actriia antagonists and uses for promoting bone growth
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
EP3181580A1 (en) * 2006-11-02 2017-06-21 Acceleron Pharma Inc. Alk1 receptor and ligand antagonists and uses thereof
ES2415666T3 (es) * 2007-02-01 2013-07-26 Acceleron Pharma, Inc. Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIa para uso en la prevención o el tratamiento de metástasis de cáncer de mama o pérdida ósea relacionada con el cáncer de mama
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
EP2140005B1 (en) 2007-03-19 2013-12-11 National Research Council of Canada Fusion proteins comprising two tgf-beta binding domains
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
EP3398966A1 (en) * 2008-05-02 2018-11-07 Acceleron Pharma, Inc. Methods and compositions for modulating angiogenesis and pericyte composition
EP2303917B1 (en) * 2008-06-26 2020-11-11 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
DK3750552T5 (da) 2008-08-14 2024-08-26 Acceleron Pharma Inc Gdf-fælder
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
EP2326670A4 (en) 2008-09-17 2014-04-16 Nat Res Council Canada HETERO MULTIVALENT BINDING AGENT FOR ELEMENTS OF THE TGF-BETA SUPERFAMILY
SG171813A1 (en) * 2008-11-26 2011-07-28 Amgen Inc Variants of activin iib receptor polypeptides and uses thereof
JP5755635B2 (ja) 2009-03-30 2015-07-29 アクセルロン ファーマ， インコーポレイテッド Ｂｍｐ−ａｌｋ３アンタゴニストおよび骨成長促進のためのその使用
KR20180026795A (ko) 2009-06-12 2018-03-13 악셀레론 파마 인코포레이티드 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
RU2573915C2 (ru) 2009-09-16 2016-01-27 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применение
FR2951408B1 (fr) 2009-10-15 2012-01-13 Renault Sa Cadre moteur pour moteur electrique de vehicule automobile
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
CA2779472C (en) * 2009-11-03 2021-03-16 Acceleron Pharma Inc. The use of a composition comprising an activin type iib receptor polypeptide in the treatment of fatty liver disease
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
CN102850458B (zh) 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途
PL2831105T3 (pl) 2012-03-28 2018-01-31 Univ Texas Fuzje receptora tgf typu ii - typu iii
US20150056199A1 (en) 2013-08-22 2015-02-26 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
WO2016090035A2 (en) 2014-12-02 2016-06-09 La Jolla Institute For Allergy And Immunology Modulators of activin and methods for modulating immune responses and t follicular helper cells
AU2016238254B2 (en) 2015-03-26 2022-05-05 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
AU2016246708B2 (en) 2015-04-06 2020-12-24 Acceleron Pharma Inc. ALK7:actRIIB heteromultimers and uses thereof
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
PT3280727T (pt) 2015-04-06 2021-04-23 Acceleron Pharma Inc Proteínas de fusão do recetor de braço único do tipo i e tipo ii e respetivas utilizações
BR112017022658A2 (pt) 2015-04-22 2018-07-17 Alivegen Usa Inc proteína isolada, molécula de ácido nucleico isolada, vetor recombinante, célula hospedeira, método de produção de uma proteína actriib híbrida, composição farmacêutica, métodos de tratamentos de distúrbios relacionados à miostatina ou relacionados à ativina a, de doença de desgaste dos músculos, de doença cardiovascular, de distúrbios metabólicos, de células cancerígenas, de doença renal, de doença inflamatória/autoimune, de uma doença de fibrose, de anemia, da dor, da condição de envelhecimento, de distúrbios ósseos, de um desgaste dos músculos ou distúrbio metabólico ou fibrótico ou inflamatório ou relacionado à ativina em indivíduos, e, método de indução do crescimento das células-tronco para o reparo de tecido ou regeneração do órgão em um indivíduo
WO2016205370A1 (en) 2015-06-15 2016-12-22 Santa Maria Biotherapeutics, Inc. Methods of using activin receptor iib-based proteins
CA2996996A1 (en) 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof
EP3439741A4 (en) 2016-04-06 2020-05-06 Acceleron Pharma Inc. ALK7 ANTAGONISTS AND USES THEREOF
WO2018009624A1 (en) 2016-07-07 2018-01-11 Acceleron Pharma Inc. Tgf-beta superfamily heteromultimers and uses thereof
WO2018009732A1 (en) 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
BR112019006993A2 (pt) 2016-10-05 2019-09-03 Acceleron Pharma Inc heteromultímeros de alk4:actriib e usos dos mesmos
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة

Also Published As

Publication number Publication date
CN107849114A (zh) 2018-03-27
CY1124247T1 (el) 2022-07-22
US20160289298A1 (en) 2016-10-06
JP7203807B2 (ja) 2023-01-13
AU2021200906A1 (en) 2021-03-04
EP3280727B1 (en) 2021-02-17
LT3280727T (lt) 2021-04-12
HRP20210411T1 (hr) 2021-04-30
AU2016246602B2 (en) 2020-11-19
ES2864850T3 (es) 2021-10-14
SI3280727T1 (sl) 2021-07-30
AU2021200906B2 (en) 2023-04-06
CN107849114B (zh) 2021-08-20
CN113683709A (zh) 2021-11-23
CA2981793A1 (en) 2016-10-13
MD3280727T2 (ro) 2021-06-30
US10358476B2 (en) 2019-07-23
CN113683708A (zh) 2021-11-23
US20200055920A1 (en) 2020-02-20
EP3280727A1 (en) 2018-02-14
JP2018517664A (ja) 2018-07-05
JP2021054839A (ja) 2021-04-08
RS61728B1 (sr) 2021-05-31
AU2016246602A1 (en) 2017-10-26
EP3280727A4 (en) 2019-02-13
WO2016164501A1 (en) 2016-10-13
US11208460B2 (en) 2021-12-28
HUE054180T2 (hu) 2021-08-30
JP6810702B2 (ja) 2021-01-06
DK3280727T3 (da) 2021-03-15
MA53883A (fr) 2021-08-18
PL3280727T3 (pl) 2021-07-19
EP3865505A1 (en) 2021-08-18
KR20170141215A (ko) 2017-12-22
PT3280727T (pt) 2021-04-23
US20220315642A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
HK1252958A1 (zh) 單臂i型和ii型受體融合蛋白和其用途
HK1250043A1 (zh) Gitrl融合蛋白及其用途
HK1244019A1 (zh) 融合蛋白
GB201509413D0 (en) Fusion protein
GB201504691D0 (en) Fusion protein
HRP20182029T1 (hr) Uti-fuzijski proteini
IL297395B1 (en) btla fusion protein agonists and uses thereof
ZA202003845B (en) Fusion proteins
HK1257937A1 (zh) 融合蛋白
GB201602850D0 (en) Fusion proteins
HK1251456A1 (zh) 免疫球蛋白融合蛋白及其用途
GB201713537D0 (en) Fusion Polypeptide
GB201503789D0 (en) Fusion polypeptide